A Phase 3 interventional study of PF-06439535 (CN) and Bevacizumab-EU in Advanced Non-squamous NSCLC, sponsored by Pfizer. Terminated at 4 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The current study will compare the efficacy, safety, pharmacokinetics and immunogenicity of PF-06439535 (CN) in combination with paclitaxel and carboplatin versus bevacizumab sourced from the European Union (bevacizumab-EU) with paclitaxel and carboplatin in Chinese participants with advanced non-squamous NSCLC in the first-line treatment setting.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-06439535 (CN) + paclitaxel + carboplatin
Drug: PF-06439535 (CN) · Drug: Paclitaxel · Drug: Carboplatin
Bevacizumab-EU + paclitaxel + carboplatin
Drug: Bevacizumab-EU · Drug: Paclitaxel · Drug: Carboplatin
15 mg/kg, IV on day 1 of each 21 day cycle for up to 2 years, or until progression or unacceptable toxicity develops.
15 mg/kg, IV on day 1 of each 21 day cycle until disease progression, unacceptable toxicity or 25 weeks. At Week 25, the participants with clinical benefit will received PF-06439535 (CN) monotherapy for up to 2 years from randomization in this study
Also known as: Avastin
175 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
AUC 5 (max=750mg) via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
Percentage of Participants Achieving Objective Response
Objective response referred to complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (non-progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions, normal nodes (target nodes must decrease to normal size); PR: \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.
Time frame: From Week 1 to Week 25 (25 Weeks)
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) in Treatment Period
TEAE was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event (AE) that worsens after the beginning of the investigational product. Serious adverse events (SAE) were assessed by the investigator. Severity of AE was graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.
Time frame: From Day 1 to end of Cycle 8; 1 Cycle = 21 Days
Number of Participants With Anti-Drug Antibodies (ADA)
ADA have been evaluated in studies with bevacizumab in cancer patient populations. A sensitive and specific immunoassay for detecting ADA in human serum was used to analyze the ADA samples (blood samples for assessment of ADA collected at specified timepoints).
Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days
Number of Participants With NAb
Blood samples for assessment of ADA and NAb were collected at specified time point. Samples that were determined positive for ADA were further characterized for NAb using a single validated NAb assay.
Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 1 Cycle = 21 Days
Trough and Apparent Peak PF-06439535 (CN) and Bevacizumab (EU) Concentrations
The drug concentrations were determined using serum samples collected at the time points specified.
Time frame: Pre-dose on Day 1 of Cycle 1 and Cycle 5, and before the last administration of the investigational product (up to Cycle 14 Day 1); 2.5 hours after initiation of bevacizumab infusion on Day 1 of Cycle 1 and Cycle 5; 1 Cycle = 21 Days
Number of Participants With TEAEs in Extension Period
Treatment emergent adverse event (TEAE) was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event that worsens after the beginning of the investigational product. Serious adverse events were assessed by the investigator. Severity of AE was graded based on NCI CTCAE version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.
Time frame: Cycle 9 Day 1 up to End of Treatment (up to Cycle 14 Day 21); 1 Cycle = 21 Days
The study was terminated on 17 March 2021 by the Sponsor. This study was conducted in China.
| Milestone | PF-06439535 (CN) | Bevacizumab (EU) |
|---|---|---|
| Started | 4 | 4 |
| Completed | 3 | 1 |
| Not completed | 1 | 3 |
| Withdrew: Study terminated by sponsor | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
Objective response referred to complete response (CR) or partial response (PR) by Week 19 of the study in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 which was subsequently confirmed by Week 25. A participant achieved CR if both target and non-target lesions achieved CR, no new lesions; achieved PR if target lesions achieved CR or PR, non-target lesions were assessed as non-CR/non-PD (non-progressive disease), indeterminate or missing, and no new lesions. For target lesions, CR: complete disappearance of all target lesions, normal nodes (target nodes must decrease to normal size); PR: \>= 30% decrease under baseline of the sum of diameters of all target measurable lesions. For non-target lesions, CR: disappearance of all non-target lesions and normalization of tumor marker levels and all lymph nodes must be normal in size; non-CR/non-PD: persistence of any non-target lesions and/or tumor marker level above the normal limits.
No measurements were reported for this outcome.
TEAE was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event (AE) that worsens after the beginning of the investigational product. Serious adverse events (SAE) were assessed by the investigator. Severity of AE was graded based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.
| Participants | PF-06439535 (CN) | Bevacizumab (EU) |
|---|---|---|
| Participants with all causalities AEs | 4 | 4 |
| Participants with all causalities SAEs | 1 | 2 |
| Participants with all causalities AEs of maximum grade 3 or 4 | 2 | 3 |
| Participants with all causalities AEs of maximum grade 5 | 0 | 0 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs | 4 | 4 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related SAEs | 0 | 1 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 3 or 4 | 1 | 2 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 5 | 0 | 0 |
ADA have been evaluated in studies with bevacizumab in cancer patient populations. A sensitive and specific immunoassay for detecting ADA in human serum was used to analyze the ADA samples (blood samples for assessment of ADA collected at specified timepoints).
| Participants | PF-06439535 (CN) | Bevacizumab (EU) |
|---|---|---|
| Cycle 1_Day 1_ADA Positive | 0 | 0 |
| Cycle 5_Day 1_ADA Positive | 0 | 0 |
| End of Treatment Positive | 0 | 0 |
Blood samples for assessment of ADA and NAb were collected at specified time point. Samples that were determined positive for ADA were further characterized for NAb using a single validated NAb assay.
No measurements were reported for this outcome.
The drug concentrations were determined using serum samples collected at the time points specified.
No measurements were reported for this outcome.
Treatment emergent adverse event (TEAE) was defined as any adverse event that occurs after the beginning of the investigational product or any pre-existing adverse event that worsens after the beginning of the investigational product. Serious adverse events were assessed by the investigator. Severity of AE was graded based on NCI CTCAE version 4.03: Grade 3-SEVERE AE; Grade 4-LIFE-THREATENING consequences; urgent intervention indicated; Grade 5-DEATH RELATED TO AE.
| Participants | Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN) |
|---|---|
| Participants with all causality AEs | 3 |
| Participants with all causality SAEs | 1 |
| Participants with all causality AEs of maximum grade 3 or 4 | 1 |
| Participants with all causality AEs of maximum grade 5 | 0 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs | 2 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related SAEs | 0 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 3 or 4 | 1 |
| Participants with PF-06439535 (CN) or bevacizumab (EU)-related AEs of maximum grade 5 | 0 |
Collected over From ICD through and up to 28 days after last dose of investigational product or prior to the start of new anticancer therapy, whichever occurred first (up to 311 days).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Period: PF-06439535 (CN) | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| Treatment Period: Bevacizumab (EU) | 0/4 (0%) | 2/4 (50%) | 4/4 (100%) |
| Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Event | Treatment Period: PF-06439535 (CN) | Treatment Period: Bevacizumab (EU) | Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN) |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 1/4 | 2/4 | 0/3 |
| PneumoniaInfections and infestations | 1/4 | 0/4 | 1/3 |
| PyrexiaGeneral disorders | 0/4 | 1/4 | 0/3 |
| Event | Treatment Period: PF-06439535 (CN) | Treatment Period: Bevacizumab (EU) | Extension Period: PF-06439535 (CN) or Bevacizumab (EU) > PF-06439535 (CN) |
|---|---|---|---|
| HyponatraemiaMetabolism and nutrition disorders | 4/4 | 0/4 | 2/3 |
| AnaemiaBlood and lymphatic system disorders | 3/4 | 1/4 | 2/3 |
| Neutrophil count decreasedInvestigations | 1/4 | 3/4 | 1/3 |
| White blood cell count decreasedInvestigations | 3/4 | 3/4 | 1/3 |
| AlopeciaSkin and subcutaneous tissue disorders | 2/4 | 3/4 | 0/3 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 1/4 | 1/4 | 2/3 |
| ProteinuriaRenal and urinary disorders | 1/4 | 1/4 | 2/3 |
| VertigoEar and labyrinth disorders | 2/4 | 0/4 | 0/3 |
| DiarrhoeaGastrointestinal disorders | 1/4 | 2/4 | 0/3 |
| NauseaGastrointestinal disorders | 2/4 | 2/4 | 1/3 |
| Age, Customized(Participants) | PF-06439535 (CN) | Bevacizumab (EU) | Total |
|---|---|---|---|
| Number | NA | NA | NA |
| Sex: Female, Male(Participants) | PF-06439535 (CN) | Bevacizumab (EU) | Total |
|---|---|---|---|
| Female | NA | NA | NA |
| Male | NA | NA | NA |
| Race (NIH/OMB)(Participants) | PF-06439535 (CN) | Bevacizumab (EU) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jun 2020 to primary completion in May 2021, 10 months.
Results were first posted in Oct 2024, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bevacizumab